815 related articles for article (PubMed ID: 26492415)
1. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
[TBL] [Abstract][Full Text] [Related]
2. Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy.
Girard A; Jouneau S; Chabanne C; Khouatra C; Lannes M; Traclet J; Turquier S; Delaval P; Cordier JF; Cottin V
Respiration; 2015; 90(3):220-8. PubMed ID: 26277885
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.
Wang L; Jin YZ; Zhao QH; Jiang R; Wu WH; Gong SG; He J; Liu JM; Jing ZC
Int J Chron Obstruct Pulmon Dis; 2017; 12():3353-3360. PubMed ID: 29200842
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
6. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary hypertension in chronic lung diseases.
Seeger W; Adir Y; Barberà JA; Champion H; Coghlan JG; Cottin V; De Marco T; Galiè N; Ghio S; Gibbs S; Martinez FJ; Semigran MJ; Simonneau G; Wells AU; Vachiéry JL
J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D109-16. PubMed ID: 24355635
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
9. Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
Ando K; Kuraishi H; Nagaoka T; Tsutsumi T; Hoshika Y; Kimura T; Ienaga H; Morio Y; Takahashi K
Lung; 2015 Dec; 193(6):911-8. PubMed ID: 26453478
[TBL] [Abstract][Full Text] [Related]
10. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
11. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension.
Woods PR; Taylor BJ; Frantz RP; Johnson BD
Am J Cardiol; 2012 Apr; 109(7):1066-72. PubMed ID: 22245407
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
13. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of vasodilator therapy in pulmonary hypertension due to COPD: a retrospective analysis.
Fossati L; Müller-Mottet S; Hasler E; Speich R; Bloch KE; Huber LC; Ulrich Somaini S
Lung; 2014 Dec; 192(6):987-95. PubMed ID: 25348430
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary arterial hypertension: a current review of pharmacological management.
Sahni S; Ojrzanowski M; Majewski S; Talwar A
Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
[TBL] [Abstract][Full Text] [Related]
16. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
Small M; Piercy J; Pike J; Cerulli A
Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
[TBL] [Abstract][Full Text] [Related]
17. Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension.
Xu QX; Yang YH; Geng J; Zhai ZG; Gong JN; Li JF; Tang X; Wang C
Chin Med J (Engl); 2017 Feb; 130(4):382-391. PubMed ID: 28218209
[TBL] [Abstract][Full Text] [Related]
18. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
19. Role of vasoactive intestinal peptide in chronic obstructive pulmonary disease with pulmonary hypertension.
Lacedonia D; Valerio G; Palladino GP; Carpagnano GE; Correale M; Di Biase M; Foschino Barbaro MP
Rejuvenation Res; 2014 Feb; 17(1):33-9. PubMed ID: 24228853
[TBL] [Abstract][Full Text] [Related]
20. [The current pharmacotherapy of pulmonary arterial hypertension].
Betkier-Lipińska K; Ryczek R; Cwetsch A
Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
